Exon Skipping and Duchenne Muscular Dystrophy Therapy: Selection of the Most Active U1 snRNA Antisense Able to Induce Dystrophin Exon 51 Skipping
Open Access
- 1 September 2010
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (9) , 1675-1682
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatmentProceedings of the National Academy of Sciences, 2008
- Dystrophin, its interactions with other proteins, and implications for muscular dystrophyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Therapeutic Modulation of DMD Splicing by Blocking Exonic Splicing Enhancer Sites with Antisense OligonucleotidesAnnals of the New York Academy of Sciences, 2006
- Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon SkippingScience, 2004
- Correction of disease-associated exon skipping by synthetic exon-specific activatorsNature Structural & Molecular Biology, 2003
- Function and Genetics of Dystrophin and Dystrophin-Related Proteins in MusclePhysiological Reviews, 2002
- Control of myogenesis in the mouse myogenic C2 cell line by medium composition and by insulin: Characterization of permissive and inducible C2 myoblastsDifferentiation, 1988
- An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics, 1988
- Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individualsCell, 1987
- Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy geneNature, 1986